Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.  Full results from a late-stage trial show that adding Amgen's Imdelltra to AstraZeneca's Imfinzi drug slashed the risk of death by 58% in patients with extensive-stage small cell lung cancer.

CNBC • an hour ago

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results  Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed Median Overall Survival Exceeded 37 Months in First-Line Maintenance with IMDELLTRA and Either IMFINZI or TECENTRIQ®  THOUSAND OAKS, Calif., Oct. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI® (durvalumab) reduced the risk of death by 58% as a first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC) (hazard ratio [HR]: 0.42; 95% confidence interval [CI]: 0.32, 0.54; P

PRNewsWire • an hour ago

At Amgen, Sustainability Is A Companywide Commitment

Amgen integrates sustainability goals in every part of its business with a holistic and innovative approach to manufacturing.

Investors Business Daily • Oct 23, 2026

Here's Why Amgen (AMGN) Fell More Than Broader Market

Amgen (AMGN) closed at $439.26 in the latest trading session, marking a -1.79% move from the prior day.

Zacks Investment Research • 17 hours ago

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

When a drugmaker's top product loses patent protection, the dividend usually takes the hit.

24/7 Wall Street • 21 hours ago

Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different

Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades.

24/7 Wall Street • a day ago

Amgen (AMGN) Gains As Market Dips: What You Should Know

Amgen (AMGN) closed at $447.28 in the latest trading session, marking a +2.04% move from the prior day.

Zacks Investment Research • Oct 22, 2026

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen maintains a diverse portfolio focused on oncology, rare diseases, and inflammation while providing steady cash flow generation. Eli Lilly & Co. continues to see explosive growth driven by its dominant position in the cardiometabolic and incretin drug markets.

The Motley Fool • Oct 22, 2026

TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS

Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52 Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52 THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52 in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis (EoE).1,2  CROSSING evaluated TEZSPIRE 210 mg and 420 mg administered subcutaneously every four weeks.

PRNewsWire • Oct 20, 2026

Here's Why Amgen (AMGN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Oct 20, 2026